A Seeking Alpha analysis tags Cigna a Hold, challenging the broad Buy consensus. The dissenting view flags PBM margin risk from FTC scrutiny and slower earnings growth. The next test is the Q3 report in October.
Cigna (CI) draws a strong Buy consensus from sell-side analysts. The bull case is straightforward: a diversified health services model anchored by the Evernorth pharmacy benefit manager and a growing specialty pharmacy business, alongside buyback-driven EPS growth.
A dissenting analysis published on Seeking Alpha argues the risk/reward is more balanced than the consensus implies. The analysis assigns Cigna a Hold rating, citing valuation and margin threats that the broader market has not fully priced in.
Cigna's Evernorth unit is one of the three largest PBMs in the U.S., alongside CVS Health's Caremark and UnitedHealth's OptumRx. The core of the bearish counter-argument, the analysis said, is the regulatory pressure on PBM margins. The Federal Trade Commission has escalated its inquiry into drug pricing practices, and bipartisan legislation targeting PBM transparency is advancing in Congress. Evernorth generates a significant share of Cigna's operating profit; any compression in PBM margins would directly cap earnings growth, the analysis said.
The valuation argument, the analysis said, is tied to growth. Cigna trades at roughly 12x forward earnings, a discount to its own five-year average. The Hold thesis does not dispute the discount. It argues the discount is justified. The analysis said Cigna's earnings growth lags behind peers such as UnitedHealth and Elevance, and the buyback-driven EPS growth model is mechanically weaker when the stock is not deeply undervalued. AlphaScala's proprietary model assigns Cigna a score of 46 out of 100, labeling the stock "Mixed."
The bull case isn't without merit. The Hold analysis acknowledges Cigna's strengths, including its strong balance sheet and growing specialty pharmacy franchise. The author also cites management's disciplined capital allocation. The disagreement, at its core, is over the margin of safety.
The next test for the conflicting views is the company's third-quarter earnings report, due in late October. Management's guidance for 2025 operating margins and PBM segment revenue will either confirm the resilience the consensus expects or validate the caution of the Hold-rated analysis.
Drafted by a large language model from the source reporting linked above, then screened by automated publishing checks. It is not read by a journalist before publication. Some articles cite our Alpha Score. Verify prices and figures against the original source. Educational coverage, not personalized advice.